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www.jacc-interventions.org to view.Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary
Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry)207Kristina Hambraeus, Karin Jensevik, Bo Lagerqvist, Bertil Lindahl, Roland Carlsson,
Ramin Farzaneh-Far, Thomas Kellerth, Elmir Omerovic, Gregg Stone,
Christoph Varenhorst, Stefan JamesCompleteness of revascularization in 23,342 percutaneous coronary intervention (PCI) patients with
multivessel disease in the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) was
described. One-year mortality, myocardial infarction (MI), and repeat revascularization in patients
undergoing incomplete as compared with complete revascularization was 7.1% versus 3.8%, 10.4%
versus 6.0%, and 20.5% versus 8.5%, respectively. The adjusted hazard ratio for the composite of
death, MI, or repeat revascularization at 1 year was higher in the incomplete group: 2.12 (95%
conﬁdence interval: 1.98 to 2.28; p < 0.0001). Incomplete revascularization at the time of hospital
discharge in patients with multivessel disease undergoing PCI is associated with a high risk of
recurrent events.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Incomplete Revascularization in Patients Treated With Percutaneous Coronary
Intervention: When Enough Is Enough216Nir Ayalon, Alice K. Jacobs
Randomized Comparison of Different Thienopyridine Loading Strategies in Patients
Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial219Willibald Hochholzer, Michael Amann, Alexander Titov, Iris Younas, Nikolaus Löffelhardt,
Florian Riede, Clemens Potocnik, Christian Stratz, Dieter Hauschke, Dietmar Trenk,
Franz-Josef Neumann, Christian M. ValinaEffective platelet inhibition at the start of a percutaneous coronary intervention reduces the risk of
ischemic complications. This randomized trial investigated to what extent loading with prasugrel 30
or 60 mg can provide a more rapid peri-interventional antiplatelet effect than clopidogrel 600 mg
in stable patients undergoing a percutaneous coronary intervention (n ¼ 300). From 30 min onward,
prasugrel 60 mg achieved a stronger platelet inhibition than clopidogrel loading. Compared with
clopidogrel, prasugrel 60 mg was associated with a twice as fast onset of platelet inhibition.
Prasugrel 30 mg had an intermediate effect. The 30-day incidence of bleeding events was not
different among the 3 groups.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Deﬁning a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing
Ad Hoc Percutaneous Coronary Intervention228Dominick J. Angiolillo, Francesco Franchi
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FEBRUARY 8, 2016 VOLUME 9, NUMBER 3Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in
Patients With Acute ST-Segment Elevation Myocardial Infarction: The BEtA-Blocker
Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial231Fikret Er, Kristina M. Dahlem, Amir M. Nia, Erland Erdmann, Johannes Waltenberger,
Martin Hellmich, Kathrin Kuhr, Minh Tam Le, Tina Herrfurth, Zulfugar Taghiyev,
Esther Biesenbach, Dilek Yüksel, Aslihan Eran-Ergöknil, Maria Vanezi,
Evren Caglayan, Natig GassanovThe Beat-AMI (BEtA-Blocker Therapy in Acute Myocardial Infarction trial was designed to evaluate
the effect of continuous intravenous esmolol infusion for 24 h in 100 patients with successful
percutaneous coronary intervention and acute ST-segment elevation myocardial infarction (STEMI).
The prospective, randomized and placebo-controlled trial revealed that esmolol treatment
signiﬁcantly decreased troponin T, creatine kinase, creatine kinase subunit MB, and n-terminal
brain natriuretic peptide release as surrogate markers for myocardial injury in patients with STEMI.
The results indicate that esmolol-induced heart rate control may limit myocardial damage in STEMI.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Accelerate and Decelerate in Primary Percutaneous Coronary Intervention 241
Jan J. Piek, Martijn A. van LavierenSTRUCTURAL Predictors of Permanent Pacemaker Implantations and New-Onset Conduction
Abnormalities With the SAPIEN-3 Balloon-Expandable Transcatheter Heart Valve244Oliver Husser, Costanza Pellegrini, Thorsten Kessler, Christof Burgdorf, Hannah Thaller,
N. Patrick Mayr, Albert M. Kasel, Adnan Kastrati, Heribert Schunkert,
Christian HengstenbergThe incidence and predictors of conduction abnormalities (CAs) and permanent pacemaker
implantations (PPIs) after transcatheter aortic valve replacement with the balloon-expandable
SAPIEN-3 (Edwards Lifesciences, Irvine, California) are unclear. A total of 208 patients without
previous pacemaker and 184 without baseline CA were analyzed. Independent predictors of CA or
PPI were implantation depth at septal side (odds ratio [OR]: 1.063 [95% conﬁdence interval (CI):
1.017 to 1.110]; p ¼ 0.006 per % of frame below the aortic annulus), prosthesis oversizing (OR:
3.489 [95% CI: 1.236 to 9.848]; p ¼ 0.018), and QRS duration (OR: 1.033 [95% CI: 1.011 to
1.056]; p ¼ 0.003 per ms). Avoidance of deep implantation and extreme oversizing may reduce
PPI and CA.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Transcatheter Aortic Valve Replacement and New Conduction Abnormalities/Permanent
Pacemaker: Can We Achieve the Intended Implant Depth?255Nicolo Piazza, Pascal Lauzier, Darren Mylotte
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FEBRUARY 8, 2016 VOLUME 9, NUMBER 3PERIPHERAL Wound Healing Outcomes and Health-Related Quality-of-Life Changes in the
ACHILLES Trial: 1-Year Results From a Prospective Randomized Controlled Trial of
Infrapopliteal Balloon Angioplasty Versus Sirolimus-Eluting Stenting in Patients With
Ischemic Peripheral Arterial Disease259Konstantinos Katsanos, Stavros Spiliopoulos, Athanasios Diamantopoulos,
Dimitris Siablis, Dimitris Karnabatidis, Dierk ScheinertThe authors report the wound healing outcomes, health-related quality-of-life (HRQOL) changes and
quality-adjusted life-years (QALYs) gain in 200 patients randomly assigned between sirolimus-
eluting stents (SES) or plain balloon angioplasty (PTA) of the infrapopliteal arteries (ACHILLES
[Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial
Disease] multicenter randomized trial; NCT00640770). HRQOL data were collected up to 1 year,
and 109 open wounds were documented at baseline. SES showed signiﬁcantly improved wound
healing progress at 6 months and overall accelerated wound closure at 1 year. There was also a
trend of more QALYs gained with SES compared with PTA up to 1 year after randomization.n EDITORIAL COMMENT
ACHILLES and the Achilles Heel of Peripheral Vascular Intervention 268
Beau M. Hawkins
Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for
Treating Femoropopliteal Artery Disease in Japan: 12-Month Results271Hiroyoshi Yokoi, Takao Ohki, Kimihiko Kichikawa, Masato Nakamura, Kimihiro Komori,
Shinsuke Nanto, Erin E. O’Leary, Aaron E. Lottes, Scott A. Snyder, Michael D. DakeThis post-market surveillance study in Japan evaluates the paclitaxel-coated Zilver PTX stent in
real-world patients with complex superﬁcial femoral artery lesions. Consecutive patients (N ¼
907) with symptomatic peripheral artery disease were treated with the drug-eluting stent (DES) in
this study. Lesions were complex with an average length of 14.7 cm, 41.6% total occlusions, and
18.6% in-stent restenosis. Freedom from TLR was 91.0%, primary patency was 86.4%, and
clinical beneﬁt (i.e., freedom from persistent or worsening symptoms of ischemia) was 87.7%
through 12 months. These results conﬁrm the beneﬁt of the Zilver PTX DES in a real-world patient
population.n EDITORIAL COMMENT
Drug-Eluting Stents in the Superﬁcial Femoral Artery: Real-World Versus
Randomized Clinical Trials; You Choose, But Caveat Emptor!278Andrew J. Klein
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FEBRUARY 8, 2016 VOLUME 9, NUMBER 3TRANSLATIONAL Beneﬁcial Effects of a Novel Bioabsorbable Polymer Coating on Enhanced Coronary
Vasoconstricting Responses After Drug-Eluting Stent Implantation in Pigs in Vivo281Kensuke Nishimiya, Yasuharu Matsumoto, Hironori Uzuka, Tsuyoshi Ogata,
Michinori Hirano, Tomohiko Shindo, Yuhi Hasebe, Ryuji Tsuburaya, Takashi Shiroto,
Jun Takahashi, Kenta Ito, Hiroaki ShimokawaDrug-eluting stent (DES)-induced coronary hyperconstricting responses remain an important
concern, resulting in unremitting angina even after successful revascularization. The present study
demonstrates for the ﬁrst time that among the 3 components of DES (metal stents, polymer
coating, and antiproliferative drug), polymer coating plays a major role in the pathogenesis of
DES-induced coronary hyperconstricting responses through inﬂammatory changes and subsequent
Rho-kinase activation in pigs in vivo, which could be ameliorated by novel poly-DL-lactic acid and
polycaprolactone copolymer technology. Thus, a novel DES system mounted on poly-DL-lactic acid
and polycaprolactone copolymer could be a promising device to reduce vasomotion abnormalities
after DES implantation.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Unraveling the Biological Effects of Drug-Eluting Stents 292
Robert J. ApplegateIMAGES IN
INTERVENTION1-Year Follow-Up of Contained Aortic Root Rupture After Transcatheter Aortic
Valve Replacement295Tetsuro Oda, Takayuki Okamura, Yosuke Miyazaki, Takeshi Nakamura, Akihito Mikamo,
Yasuaki Wada, Atsuo Yamashita, Masaya Takahashi, Kentaro Hayashida,
Kimikazu Hamano, Masafumi Yano
Cancer in the Left Anterior Descending Artery: A Therapeutic Aspect
of Thrombus Aspiration?297Dieter Dauwe, Nick Hiltrop, Willem Schurmans, Philippe Moerman, Jan Bogaert,
Stefan Janssens, Mark Coosemans
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